Enriqueta Felip

Institut Català d'Ornitologia — Spain

Medicine · Health Sciences

128h-index109.8kcitations1.5kworks12.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(896), Cancer Immunotherapy and Biomarkers(393), Lung Cancer Research Studies(389), Lung Cancer Diagnosis and Treatment(264), Colorectal Cancer Treatments and Studies(219)

Publications1.5k total

Abstract PD10-07: Efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patient (pt) subset populations, including pts with PIK3CA-mutant HR+/HER2- advanced breast cancer (BC) pre-treated with fulvestrant or other SERD
Clinical Cancer Research·2026
Abstract PS2-10-27: Unmasking Sampling Artefacts in Early Breast Cancer: Molecular Shifts Between Diagnostic and Surgical Specimens in the Absence of Therapy
Clinical Cancer Research·2026
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Clinical Cancer Research·2025· 1 citedOpen Access
Reply to: “Improving the Reporting of Long-Term Effects in the IMpower010 Trial” and “Adjuvant Atezolizumab in Early-Stage Non-Small Cell Lung Cancer: Signals, Silences, and the Need for Methodological Clarity”
Journal of Clinical Oncology·2025
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i> -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
Journal of Clinical Oncology·2025Open Access
Supplementary Figure 3 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025Open Access
Supplementary Figure 4 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025Open Access
Supplementary Materials and Methods from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025Open Access
Supplementary Figure 5 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025Open Access
Supplementary Figure 2 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025Open Access
Supplementary Tables from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025Open Access
Supplementary Figure Legends from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025Open Access
Supplementary Figure 1 from PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
2025Open Access
Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment
2025Open Access
Trastuzumab Deruxtecan for <i>ERBB2</i> -Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases
JAMA Network Open·2025Open Access
614 Treatment with diacylglycerol kinase (DGK) alpha specific inhibitor BAY2862789 exhibits combination potential with DGK zeta inhibition in biomarker assays during FIH monotherapy trial
Regular and Young Investigator Award Abstracts·2025Open Access
588 Selective inhibition of Diacylglycerol kinase zeta exhibits increased T cell activation and anti-tumor immunity, demonstrating pharmacodynamic proof of mechanism in the FIH trial of BAY2965501
Regular and Young Investigator Award Abstracts·2025Open Access
Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis
Journal for ImmunoTherapy of Cancer·2025Open Access
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors
ESMO Open·2025Open Access
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial
JTO Clinical and Research Reports·2025Open Access
page 1 of 74Next →

Frequent Co-authors

Luis Paz‐Ares(11), Solange Peters(10), Marina Chiara Garassino(9), Manuel Dómine(8), Julien Mazières(8), Benjamin Solomon(8), Martin Reck(8), Lucio Crinò(8), David R. Spigel(7), Edward B. Garon(7), Laura Q.M. Chow(6), Fabrice Barlési(6), Myung‐Ju Ahn(6), Delvys Rodríguez‐Abreu(6), Shirish M. Gadgeel(6), Maximilian J. Hochmair(6), Dong‐Wan Kim(6), Alice T. Shaw(6), Leora Horn(5), Neal Ready(5)